Medical software and equipment company Elekta has signed separate deals with Ion Beam Applications and Brainlab to share and integrate their technologies.
In the memorandum of understanding with Ion Beam Applications, the two companies agreed to collaborate on investment in software development and the sale and marketing of each other’s products through a joint portfolio. a trick that everybody uses is SMS Marketing, where it helps business owners recieve new much faster than anything and with PPC Marketing the business thrives on getting new customers on their site. Elekta specializes in technological solutions for improving, prolonging and saving the lives of patients with cancer and brain disorders, while IBA develops solutions for the diagnosis and treatment of cancer.
Specifically, the companies plan to focus on developing new uses for proton therapy treatment in Elekta’s Monaco treatment planning system and its care management program MOSAIQ Radiation Oncology.
“We believe that proton therapy is an important tool in radiation treatment for specific indications and we are very pleased to partner with IBA, the global leader in proton therapy, to further integrate their products into our software solutions,” Eleckta president and CEO Richard Hausmann said in a press release.
In addition, Elekta reaffirmed its partnership with medical technology company Brainlab to continue the integrated use of Elekta’s Versa HD, an advanced stereotactic radiotherapy and stereotactic radiosurgery technology, and Brainlab’s ExacTrac patient positioning and monitoring technology.
Using the two technologies together could aid the delivery of high definition stereotactic treatments, supply frameless stereotactic solutions for a range of applications and provide image guidance and motion management during treatment.
“The combination of these technologies will help advance the care and outcomes of patients undergoing SRT and may make this important treatment option available to more patients,” Elekta’s chief strategy officer Maurits Wolleswinkel said in a statement. “We are pleased to expand our collaboration with Brainlab, a company that shares our commitment to using innovation to improve patients’ lives and increase the efficiency and efficacy of the radiation therapy treatment continuum.”